Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...

Any significant move would also need support from Evotec’s other major shareholders — Novo Holdings A/S, the parent company of drugmaker Novo Nordisk A/S, as well as Abu Dhabi sovereign fund Mubadala ...

Evotec's other major shareholders are Novo Nordisk parent Novo Holdings and Mubadala Investment. Triton's other investments range from pharmaceutical companies Bormioli Pharma and Clinigen to tank ...

Any significant move would also need support from Evotec's other major shareholders Novo Holdings - the parent company of drugmaker Novo Nordisk - and Abu Dhabi sovereign fund Mubadala Investment ...